This observation is consistent with prior studies showing TP53/RB1 dual-mutations in 35–36% of pulmonary and extrapulmonary large cell NECs, while in more than 90% of SCLCs [37,38]. Here, TP53 is linked to large cell neuroendocrine carcinoma.